secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001171843-23-006795
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Biopharma CEO William Collier to retire Dec 31; COO McElhaugh named interim CEO
--------------------------------------------------------------------------------

- William H. Collier retires as President, CEO, and director effective Dec 31, 2023.
- Michael J. McElhaugh, Co-founder and COO, appointed interim President and CEO effective Jan 1, 2024.
- McElhaugh will also join the Board on Jan 1, 2024.
- Collier's retirement is not due to any disagreement with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323006795/0001171843-23-006795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323006795/f8k_110723.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer